Merck Sharp + Dohme Corp.

Merck + Co., Inc.

Novartis Ag

Novartis Inflammasome Research, Inc.

Nicox S.a.

Msd R&d Co., Ltd.

Dong-Ming Shen

William R Roush

Shomir Ghosh

Shankar Venkatraman

Cheng Zhu

Sander G Mills

Gary D Glick

Scott D Edmondson

Jinlong Jiang

David Guenther Winkler

Thomas H Graham

Kevin Tyler Chapman

Malcolm MacCoss

Jeffrey John Hale

Deping Wang

Dooseop Kim

Amjad Ali

Shrenik K Shah

Michael P Dwyer

Paul E Finke

Hong Shen

James B Doherty

Zhicai Wu

John S Debenham

Zhi-Cai Shi

Yimin Qian

Kun Liu

Harvey Wendt

Emma R Parmee

Peter J Sinclair

Shawn J Stachel

Daniel Vincent Paone

Christopher L Lynch

Iyassu Sebhat

Fa-Xiang Ding

Richard Thomas Beresis

Andrew William Stamford

Philip Jones

Ravi P Nargund

Neville J Anthony

Bin Hu

Melissa S Egbertson

Jason David Katz

Richard Berger

Lehua Chang

Luigi Franchi

Gregori J Morriello

Bing Li

Liping Wang

Ihor E Kopka

Stephen D Goble

Shimin Xu

Christopher Joseph Sinz

Subharekha Raghavan

Anthony K Ogawa

Robert J DeVita

Sookhee Nicole Ha

Yuguang Wang

John A McCauley

Kathleen M Rupprecht

Charles G Caldwell

Peter D Williams

Sherman Tim Waddell

Malcolm Maccoss

Robert K Baker

Lin Yan

Yong Zhang

Ravindra N Guthikonda

Ying-Duo Gao

Nicoletta Almirante

Santhosh Francis Neelamkavil

Jianmin Fu

XiaoXia Qian

Rongze Kuang

Joon Jung

Christopher Francis Thompson

Xin-Jie Chu

Wanying Sun

Mark E Scott

Christina B Madsen-Duggan

Eric Mertz

Yeon-Hee Lim

Kartik M Keertikar

Weiguo Liu

M Katharine Holloway

Wei Zhou

William D Shipe

Christopher James Bungard

Jiayi Xu

Joseph Leslie Duffy

Pei Huo

Stefano Biondi

Nicolas Zorn

David Jonathan Bennett

Kevin D Dykstra

Vincent Colandrea

Tao Ji

Meng-Hsin Chen

Deyou Sha

In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.

Compounds and compositions for treating conditions associated with NLRP activity

In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.

In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured:

In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: wherein the variables shown in Formula AA can be as defined anywhere herein. Compounds AA are modulators of NLRP1 and/or NLRP3

Sulphonamides and compositions thereof for treating conditions associated with NLRP activity

In one aspect, compounds of Formula A, or a pharmaceutically acceptable salt thereof, are featured, or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein. 

In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured. The variables shown in Formula AA are as defined in the claims. The compounds of formula AA are NLRP3 activity modulators and, as such, can be used in the treatment of metabolic disorders (e.g. Type 2 diabetes, atherosclerosis, obesity or gout), a disease of the central nervous system (e.g. Alzheimer's disease, multiple sclerosis, Amyotrophic Lateral Sclerosis or Parkinson's disease), lung disease (e.g. asthma, COPD or pulmonary idiopathic fibrosis), liver disease (e.g. NASH syndrome, viral hepatitis or cirrhosis), pancreatic disease (e.g. acute pancreatitis or chronic pancreatitis), kidney disease (e.g. acute kidney injury or chronic kidney injury), intestinal disease (e.g. Crohn's disease or Ulcerative Colitis), skin disease (e.g. psoriasis), musculoskeletal disease (e.g. scleroderma), a vessel disorder (e.g. giant cell arteritis), a disorder of the bones (e.g. osteoarthritis, osteoporosis or osteopetrosis disorders), eye disease (e.g. glaucoma or macular degeneration), a disease caused by viral infection (e.g. HIV or AIDS), an autoimmune disease (e.g. Rheumatoid Arthritis, Systemic Lupus Erythematosus or Autoimmune Thyroiditis), cancer or aging. 

The present invention relates to a compound represented by formula I': and pharmaceutically acceptable salts thereof. The compounds of formula I are inhibitors of diacylglyceride O-acyltransferase 2 ('DGAT2') and may be useful in the treatment, prevention and suppression of diseases mediated by DGAT2. The compounds of the present invention may be useful in the treatment of hepatic steatosis, diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cardiorenal diseases such as chronic kidney diseases and heart failure and related diseases and conditions. 

Indazole derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2

The present invention relates to a compound represented by formula I: and pharmaceutically acceptable salts thereof. The compounds of formula I are inhibitors of diacylglyceride O-acyltransferase 2 ('DGAT2') and may be useful in the treatment, prevention and suppression of diseases mediated by DGAT2. The compounds of the present invention may be useful in the treatment of hepatic steatosis, diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, nonalcoholic steatohepatitis (NASH), cardiorenal diseases such as chronic kidney diseases and heart failure and related diseases and conditions. 

Indole derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2

In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: 

The present invention is directed to pyrimidine carboxamide compounds of formula I which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction. 

Triazolyl pyrimidinone compounds as PDE2 inhibitors

Pyrazolyl pyrimidinone compounds as PDE2 inhibitors

The present invention is directed to pyrimidinone amide compounds which may be useful as therapeutic agents for the treatment of central nervous system and/or peripheral disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Alzheimer's, cognitive impairment, anxiety, depression, migraines, or Huntington's disease, Parkinson's disease, Parkinson's disease dementia (PDD), and other diseases associated with striatal hypofunction or basal ganglia dysfunction. 

Pyrimidinone amide compounds as PDE2 inhibitors

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma Kallikrein. 

Factor XIA inhibitors

Growing community of inventors

Edison, NJ, United States of America

Dong-Ming Shen